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Advances in Stem Cells Biology: New
Approaches to Understand Depression
A. Borsini and P. A. Zunszain
Abstract Depression is a highly prevalent complex neuropsychiatric disorder,
which ranks first among all mental and neurological disorders as a contributor to
the global burden of disease. However, available treatments are still far from ideal,
for their specificity as well as their efficacy. This situation can now be improved by
the increasing availability of stem cells, which allows the development of in vitro
human neural systems to model the brain. These models complement observations
from animal models and patients with depression, allowing for a better understand-
ing of the complexity of this psychiatric illness and potential treatments. Cells
derived from the olfactory neuroepithelium, multipotent fetal hippocampal progen-
itor cells (HPCs) and human induced pluripotent stem cells (iPSCs) have shown
promising leads. Using HPCs and iPSC-derived forebrain neurons, we managed to
provide further insights into the action of drugs with antidepressant action as well as
on molecular mechanisms underlying the effect of stress and inflammation, both
linked to the pathophysiology of depression. Particular attention has been paid to
the complex pathways by which the immune and stress systems differently deter-
mine the final developmental fate of HPCs and the synaptic plasticity of iPSCs. The
combination of accessibility and validity of the available stem cells models will
allow further work to increase our insights into the biology of depression and
support the identification of novel therapeutic targets.
Introduction
How Can We Best Study Depression?
Depression ranks first among all mental and neurological disorders as a contributor
to the global burden of disease and causes a heavy load on patients and their
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families. However, available treatments are far from ideal. Only a third of patients
respond to the initial treatment, another third will get better only after several
changes of medication and the rest will go on to be treatment resistant (Rapaport
et al. 2003; Trivedi et al. 2006). Why is this? We still do not know why depression
happens; neither do we clearly understand how antidepressants work. Much of the
current understanding about the pathogenesis of major depression has come from
animal models (Krishnan and Nestler 2011) as well as from peripheral (Felger
et al. 2012) and central nervous system (CNS; Raison et al. 2010) circulating
measurements from patients with depression. Due to the unique and complex
features of human depression, the generation of valid and more insightful depres-
sion models has been less straightforward than modeling other disabling diseases
(Krishnan and Nestler 2011). One possible approach is that of focusing on brain
models, using neural cell lines. Undifferentiated or differentiated tumor-derived
cells have been used as a translationally valid experimental model for several
psychiatric disorders, including depression (Donnici et al. 2008; Alboni
et al. 2013). However, such lines are limited in the cell types they can be made to
resemble and may have major chromosomal abnormalities (Bray et al. 2012). Into
this breach come new brain models of neural stem cells. Using multipotent fetal
hippocampal progenitor cells (HPCs) and human induced pluripotent stem cells
(iPSCs), we have mimicked clinically pertinent conditions to depressive disorders
by combining depressogenic insults and antidepressant strategies (Anacker
et al. 2011b, 2013a, b; Zunszain et al. 2012; Horowitz et al. 2015). Indeed, our
outcomes provided evidence for the efficacy of such models in understanding the
disorder as well as for giving more insights into antidepressants and their mecha-
nisms of action. Particularly, we focused on neurogenesis as a potential candidate
mechanism for the etiology of this condition as well as a substrate for antidepres-
sant action.
The Neurogenesis Theory of Depression
A reduction in hippocampal neurogenesis, that is the birth of neurons from stem
cells, has been suggested as one of the neurobiological alterations mediating the
development of depressive-like behavior in animals, particularly under conditions
of stress (David et al. 2009; Snyder et al. 2011; Surget et al. 2011). In the absence of
effective neurogenesis, the depressive-like behavior elicited in animals by stress
includes the hallmark abnormalities of clinical depression: increased hypothalamic-
pituitary-adrenal (HPA) axis activity, glucocorticoid resistance (that is, impaired
suppression of HPA axis activity by dexamethasone), anhedonia (assessed using the
sucrose preference test), and behavioural despair (assessed using the forced swim
test) (David et al. 2009; Snyder et al. 2011; Surget et al. 2011). Moreover, it has
been suggested that an impaired neurogenesis may also precipitate depressive
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symptoms because of the lack of neurogenesis-dependent cognitive functions, such
as the ability to enhance encoding of new memories and responding to contextual
changes, which may be protective against behavioural despair in the face of
repeated stressors (Sahay et al. 2011). Recent studies showing that the magnitude
of adult neurogenesis in humans is probably larger than generally believed (Snyder
and Cameron 2012; Spalding et al. 2013) provided even stronger support for the
importance of neurogenesis and its proposed involvement in the association
between stress and depression (Snyder et al. 2011).
Increased inflammation can also cause reductions in neurogenesis. Immune
molecules, including interleukin-1beta (IL-1β), IL-6, interferon-alpha (IFN-α) and
tumor necrosis factor-alpha (TNF-α) have been shown to be significantly
upregulated in the peripheral blood of depressed patients (Howren et al. 2009;
Dowlati et al. 2010). Particularly in the context of depression, IL-1β, IL6, IFN-α
and IFN-γ have also been shown to easily move from the periphery into the brain
(Dantzer et al. 2008; Najjar et al. 2013). Once they cross the brain-blood barrier,
these molecules can alter distinct molecular and cellular mechanisms, including cell
proliferation and neuronal maturation (Pickering and O’Connor 2007; Alboni
et al. 2014) associated with complex cognitive processes, such as mood and
learning functions (Makhija and Karunakaran 2013; Shigemoto-Mogami
et al. 2014). In particular, using animal models, IL-1β, IL-18, IFN-α and TNF-α,
have been shown to contribute to inhibition of synaptic plasticity and memory
consolidation (Pickering and O’Connor 2007), causing similar impairments to those
often reported in patients with major depressive disorder or in experimental models
of depression (Pollak and Yirmiya 2002; Capuron and Miller 2004; Zunszain
et al. 2013).
Furthermore, stress and inflammation interact. For example, in response to
chronic IFN-α administration, patients with Hepatitis C Virus showed a hyper-
reactivity of the HPA axis (Capuron et al. 2002; Raison et al. 2010). Most inter-
estingly, around 30% of those patients developed clinically significant depression
(Raison et al. 2009), strengthening the notion that stress and inflammation might be
among the crosstalk pathways leading to the pathogenesis of the depressive disor-
der. Indeed, it is of relevance in this context that stress and inflammation are among
the different downstream molecular mechanisms that distinct antidepressants acti-
vate. Particularly, antidepressants from the selective serotonin reuptake inhibitor
(SSRI) class, such as fluoxetine, have shown to normalize stress-induced HPA
hyperactivity in rodents (Perera et al. 2011; Surget et al. 2011), whereas other
serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants, such as
venlafaxine, have normalized inflammatory alterations in cytokine-treated
depressed patients (Capuron et al. 2002). However, irrespective of which distinct
downstream molecular mechanisms specific antidepressants activate, those path-
ways may ultimately converge to stimulate neurogenesis, which is proposed as an
essential substrate for antidepressant action (Schloesser et al. 2010).
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Experimental Approaches
Among the approaches available to investigate the complexity of depressive disor-
ders, immortalized cell lines and patient-derived stem cell lines have proved to be
relevant in vitro human neural cell models (Fig. 1). Immortalized cell lines allow
molecular, developmental and pathophysiological mechanisms to be studied with
considerable reliability. Examples of immortalized cell lines are region-specific
neural stem cells and tumour-derived cells. An alternative cell-based approach is to
derive and compare neural cells from patients and control individuals, particularly
using iPSCs or olfactory neuroepithelium-derived cell lines. Indeed, the use of cells
from patients allows a more attentive analysis of the pathological processes arising
from the whole range of genetic susceptibility variants characterizing each indi-
vidual (Srikanth and Young-Pearse 2014). Evidence has shown the significant
incidence of distinct genetic polymorphisms in patients with psychiatric conditions,
including depression (Cao et al. 2015; Chen et al. 2015; Wang et al. 2015),
suggesting the importance of using such models to investigate genetic differences,
which may allow for a predictive diagnosis of this disorder (Pasca et al. 2014). For
the purpose of this chapter we will focus on immortalized stem cells and iPSC
models. We will subsequently report our findings, providing evidence for their
efficacy in understanding depressive disorders and antidepressant mechanisms of
action.
Immortalized Human Neural Cell Lines
Neural Stem Cell Lines
Stem cells derived from human fetal brain are multipotent (i.e., they can give rise to
a range of neurons and glia) and allow developmental and physiological processes
Neural Cell Models
Immortalized human 
cell lines Patient-derived cell lines
Tumor-derived 
cell lines
Region-specific 
stem cell lines
Olfactory 
neuroepithelium-
derived stem cell 
lines 
Induced 
pluripotent 
stem cell lines 
Fig. 1 The different range of neural cell models used to study depressive disorder and mecha-
nisms of action of antidepressants
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to be studied more faithfully. Particularly, clonal neural stem cell lines can be
generated by conditional immortalization, whereby a regulated gene that drives cell
division is introduced into the cell’s genome, allowing controlled expansion and
differentiation (Pollock et al. 2006). Indeed, neural stem cell lines with normal
chromosomes have been established from several human fetal brain regions,
including cerebral cortex, hippocampus and striatum. This approach has several
unique advantages. First, it delivers data from living human brain cells, not easily
accessible in clinical samples; second, it can mimic a multitude of clinically
relevant conditions within a tightly controlled experimental environment, providing
a model system with which to explore the mechanisms of drug treatments for a
variety of psychiatric disorders; and finally, it generates findings that are directly
translatable in clinical samples (Bray et al. 2012). Using this approach, we have
modeled “depression in a dish” using the cell line HPC0A07/03C (provided by
ReNeuron Ltd, London), derived from the hippocampus, which allowed us to
translate findings from bench-to-beside-and-back (Anacker et al. 2011b, 2013a, b;
Zunszain et al. 2012; Horowitz et al. 2015). We will describe our observations in
further detail.
Modeling the Role of Stress
As a first example of our translational approach, we managed to provide
evidence for the detrimental role of stress on hippocampal neurogenesis. Impaired
neurogenesis in rodents has recently been shown to contribute to the development
of depressive-like behaviours, including anhedonia and behavioural despair in
response to acute and chronic stressful insults (Zhu et al. 2014). Using our human
hippocampal model, we showed that cortisol caused a reduction in the generation
of new neurons via glucocorticoid receptor (GR)-dependent mechanisms, an effect
which could be fully reverted by treatment with the SSRI sertraline. Indeed,
subsequent stimulation with a GR-antagonist completely abolished the increase
in neurogenesis induced by the antidepressant (Anacker et al. 2011b). Our model
proved to be effective in providing further details from the complex interaction
between stress and neuronal generation, proposing GR-dependent mechanisms as
possible future targets of antidepressant drug treatment to overcome neurogenesis-
related disturbances in depression (Anacker et al. 2011a).
Modeling the Role of Inflammation and Oxidative Stress
As a second example of the use of our model, we demonstrated the involvement of
inflammation on hippocampal neurogenesis. Previous evidence had reported that
in vitro stimulation with distinct cytokines, including IL-1β, IL-6, IFN-α and
TNF-α, caused a significant alteration in both proliferation and neuronal maturation
of human and animal cells (Borsini et al. 2015). Using our in vitro human neuronal
model, we investigated the effect of two pro-inflammatory cytokines, IFN-α
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(our unpublished observation) and IL-1β (Zunszain et al. 2012), on neurogenesis.
Findings showed that, upon treatment with both cytokines HPCs developed a
“depressive phenotype” comprising reduced neurogenesis. Moreover, IL-1β was
responsible for alterations in transcription pathways regulating the metabolism of
tryptophan. Indeed, the inhibitory effects of IL-1β on neurogenesis were mediated,
at least in part, by activation of the neurotoxic branch of the kynurenine pathway,
one of the main pathways postulated to be involved in the development of depres-
sive disorders (Baranyi et al. 2015).
A third example involved the use of tert-butylhydroxiperoxide (TBHP) to model
oxidative stress. High levels of reactive oxygen species, shown in depressed
patients, are known to affect cellular constituents, leading to neoepitopes and
damage-associated molecular patterns that promote further immune responses
(Bakunina et al. 2015). Cells treated with TBHP showed a dose-dependent increase
in lipid peroxidation as well as reduced cell viability.
Studying Mechanism of Action of Antidepressants
Finally, we used this model to investigate the immunomodulatory properties of
distinct compounds with antidepressant actions. We explored the effects of several
conventional monoaminergic antidepressants and the omega-3 polyunsaturated
fatty acids (n-3 PUFAs), eicosapentanoic acid (EPA) and docosahexanoic acid
(DHA), on HPCs treated with the inflammatory and depressogenic IL-1β. In
contrast to sertraline and DHA, which had pro-inflammatory properties,
venlafaxine and EPA were shown to have anti-inflammatory effects via decreasing
distinct cytokines, including IL-6, IL-8 and IP-10 (Horowitz et al. 2015). In
addition, these compounds showed differential effects on neurogenesis. Again,
the findings demonstrate the efficacy of this model for studying specific mecha-
nisms of action of drugs with antidepressant action.
Tumour-Derived Cell Lines
These lines, with an ability to expand quite readily in culture, provide a standard-
ized and potentially limitless alternative to study intracellular mechanisms of
antidepressant action. Currently, the most commonly used human neural cell line
is SH-SY5Y. This line displays neuronal properties, including neurite outgrowth,
neurotransmitter synthesis and relevant receptor expression. The SH-SY5Y line has
been widely used to study intracellular mechanisms of different antidepressant
action, including the SSRI sertraline, the selective norepinephrine reuptake inhib-
itor (SNRI) desipramine and the norepinephrine–dopamine reuptake inhibitor
(NDRI) bupropion (Lin 2015).
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Patient-Derived Neural Cells
IPSCs
Among the patient-derived cell models, iPSC technology provides distinct cell
types that are considered to be central to psychiatric disorders, such as those of
the cortex and the hippocampus (Jaworska et al. 2015). Indeed, primary somatic
cells, typically from skin, can be taken from an individual and reprogrammed into
pluripotent stem cells that can give rise to all of the cell types that characterize the
body, including those of the CNS. By capturing a patient’s entire genome and any
possible epigenetic variations, iPSCs constitute a unique source of material for
studying neurodevelopmental features of psychiatric disorders in vitro.
Reports are now beginning to emerge in which this technology has been applied
to cells taken from psychiatric patients. For example, human keratinocytes from
healthy controls and patients with bipolar depression have been reprogrammed into
cortical neurons. When compared with control cells, neurons derived from patients
with bipolar depression showed an alteration in the expression of transcripts that
regulate Hedgehog signaling (Cheung et al. 2009), as well as modulations in key
components of the mTOR pathway (O’Shea and McInnis 2015), which have both
been shown to be among the mechanisms involved in the development of depres-
sive disorders (Rajendran et al. 2009; Ignacio et al. 2015). Using iPSC-derived
forebrain neurons, we showed that ketamine, known to have fast-acting antidepres-
sant efficacy in treatment-resistant patients, was able to rescue the detrimental
effects produced by treatment with IL-1β and to increase the number of presynaptic
and postsynaptic proteins.
Olfactory Neuroepithelium-Derived Stem Cells
Cells from the olfactory mucosa, which can be extracted through biopsy, can easily
propagate, forming neurospheres of neural stem cells and differentiating neural
progenitor cells. Although there are no studies using olfactory neuroepithelium-
derived cells from depressed patients, they have been used to study schizophrenia
(Matigian et al. 2010; Fan et al. 2012), suggesting the importance of using such
models to investigate genetic differences, which may allow for a predictive diag-
nosis of depression in certain individuals.
Conclusions and Limitations of the Cell Models
Stem cell-based approaches to study psychiatric disorders are advancing on two
main fronts. On one hand, clonal cell lines which accurately model the CNS are
being used in controlled experiments to assess the mechanisms of antidepressant
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action for psychiatric disorders, which might in the short term lead to advancements
in therapeutic strategies for these conditions. On the other hand, patient-derived
cells and cells from control patients allow the study of pathological processes
deriving from the multiple genetic susceptibility variants, which can now be
investigated with more accuracy. However, both cell models have some limitations
that need to be pointed out. Although human neural cell lines can be used to
investigate the molecular and cellular functions of individual susceptibility genes,
they do not capture the many genetic variables that contribute to the development of
psychiatric disorders (Bray et al. 2012). Patient-derived cell lines offer the advan-
tage of capturing each individual’s whole genome, but there is limited knowledge
as to which cell types are most relevant to study specific psychiatric conditions
(Sandoe and Eggan 2013). In addition, while iPSC technology can model the effects
of medications, these cells may lose the effects of environmental influences that
may contribute to the development of the psychiatric illnesses, such as stressors or
negative life events (Okano and Yamanaka 2014).
Although cell-based models are still unable to elucidate the molecular complex-
ity of psychiatric illnesses, the enormous progress in stem cell technologies has
revolutionized the field of “in vitro disease modeling,” providing not only a window
into the mechanisms underlying the depressive disorder but also a platform for
screening novel therapeutic strategies for the prevention and treatment of this
condition.
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